Follow Us:
Miltefosine Exporter From India

Miltefosine

Miltefosine is an oral antiprotozoal medicine used to treat visceral, cutaneous, and mucosal leishmaniasis caused by susceptible Leishmania species. It works by disrupting parasite cell membrane function and interfering with essential cellular processes, leading to parasite death. It is available as oral capsules and is administered according to the type of infection, patient characteristics, and approved treatment protocol. Common side effects include nausea, vomiting, diarrhoea, abdominal pain, and reduced appetite. Miltefosine can cause kidney and liver toxicity and is strongly contraindicated during pregnancy because of the risk of fetal harm; effective contraception is required during treatment and for the specified period afterwards. Treatment should be prescribed under specialist supervision, with appropriate pregnancy assessment and monitoring of kidney and liver function.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Miltefosine

Miltefosine was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Miltefosine

Availability of Miltefosine

Delivery of Miltefosine

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Miltefosine.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Miltefosine.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Miltefosine, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Miltefosine Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Miltefosine

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Miltefosine Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Miltefosine, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Miltefosine

The export of Miltefosine from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Miltefosine Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Miltefosine specifications, certificates of analysis, and other supporting documents required for Miltefosine export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Miltefosine export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Miltefosine regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Miltefosine documentation, labelling, Miltefosine manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Miltefosine Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Miltefosine, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.